Construction, Stability, and Activity of Multivalent Circular Anticoagulant Aptamers*

Here we describe the design and construction of multivalent circular DNA aptamers. Four aptameric binding motifs directed at blood-borne targets are used as a model set from which larger, multidomain aptamers are constructed in a straightforward manner. Intra- or intermolecular ligation of precursor oligonucleotides provides a stabilizing mechanism against degradation by the predominant exonuclease activity of blood products without the need for post-selection chemical modification. In many cases, circular DNA aptamer half-lives are extended beyond 10 h in serum and plasma, making such constructs viable for therapeutic and diagnostic applications. Duplexes and three-way junctions are used as scaffold architectures around which two, three, or four aptameric motifs can be arranged in a structurally defined manner, giving rise to improved binding characteristics through stability and avidity gains. Circular aptamers targeted against thrombin display improved anticoagulant potency with EC50 values 2–3-fold better than those of the canonical GS-522 thrombin DNA aptamer. Intrinsic duplex regions provide an opportunity to incorporate additional transcription factor binding motifs, whereas ancillary loops can be used to provide further functionality. These anticoagulant aptamers provide a starting point for merging the principles of DNA nanotechnology with aptameric functions.

[1]  A. Doherty,et al.  Nick recognition by DNA ligases. , 2000, Journal of molecular biology.

[2]  N. Seeman,et al.  Synthesis from DNA of a molecule with the connectivity of a cube , 1991, Nature.

[3]  Y. Cho‐Chung,et al.  Oligonucleotides as transcription factor decoys. , 1999, Current opinion in molecular therapeutics.

[4]  M. Famulok,et al.  Oligonucleotide libraries--variatio delectat. , 1998, Current opinion in chemical biology.

[5]  F. J. Overmars,et al.  Solution structure of a DNA three-way junction containing two unpaired thymidine bases. Identification of sequence features that decide conformer selection. , 2000, Journal of molecular biology.

[6]  D. Klinman,et al.  Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. , 2003, Clinical immunology.

[7]  Siqing Shan,et al.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Visser,et al.  Measurement of intracellular (compartmental) pH by 31P NMR in Aspergillus niger. , 2000, Journal of biotechnology.

[9]  A. Levin.  A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. , 1999, Biochimica et biophysica acta.

[10]  Young-Chae Chang,et al.  E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. , 2003, Biochemical and biophysical research communications.

[11]  H. Schluesener,et al.  Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels , 2001, The Journal of Biological Chemistry.

[12]  F. Quadrifoglio,et al.  G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells. , 2004, Biochemistry.

[13]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[14]  M F Kubik,et al.  Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. , 1997, Journal of molecular biology.

[15]  N. Seeman.  Nucleic Acid Nanostructures and Topology. , 1998, Angewandte Chemie.

[16]  C. W. Hilbers,et al.  Structural features of the DNA hairpin d(ATCCTA-GTTA-TAGGAT): formation of a G-A base pair in the loop. , 1997, Nucleic acids research.

[17]  L. Gold,et al.  High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Bertelsen,et al.  Structural and functional characterization of potent antithrombotic oligonucleotides possessing both quadruplex and duplex motifs. , 1995, Biochemistry.

[19]  G. Weiner,et al.  CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response , 2003, Current opinion in oncology.

[20]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[21]  T. Ogihara,et al.  Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design. , 2003, Current drug targets.

[22]  J. Shaw,et al.  Modified deoxyoligonucleotides stable to exonuclease degradation in serum. , 1991, Nucleic acids research.

[23]  A. Gewirtz.  Oligonucleotide therapeutics: clothing the emperor. , 1999, Current opinion in molecular therapeutics.

[24]  Kyungsook Han,et al.  Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer , 2003, FEBS letters.

[25]  A Novel Oligodeoxynucleotide Inhibitor of Thrombin. I. In VitroMetabolic Stability in Plasma and Serum , 1995, Pharmaceutical Research.

[26]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[27]  F. J. Overmars,et al.  NMR studies of DNA three-way junctions containing two unpaired thymidine bases: the influence of the sequence at the junction on the stability of the stacking conformers. , 1996, Journal of molecular biology.

[28]  J. Toulmé,et al.  DNA Aptamers Selected Against the HIV-1trans-Activation-responsive RNA Element Form RNA-DNA Kissing Complexes* , 1999, The Journal of Biological Chemistry.

[29]  Tobias Sjöblom,et al.  Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. , 2002, Cancer research.

[30]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[31]  J. Sennello,et al.  In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. , 1997, Chemistry & biology.

[32]  A D Ellington,et al.  Aptamers as therapeutic and diagnostic reagents: problems and prospects. , 1997, Current opinion in chemical biology.

[33]  W. Wallace,et al.  Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. , 2003, Blood.

[34]  S. Jayasena.  Aptamers: an emerging class of molecules that rival antibodies in diagnostics. , 1999, Clinical chemistry.

[35]  George Georgiou,et al.  Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. , 2002, Nucleic acids research.

[36]  A. Varki,et al.  DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. , 1996, The Journal of clinical investigation.

[37]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[38]  S. de Vries,et al.  Dynamic mechanism of nick recognition by DNA ligase. , 2002, European journal of biochemistry.

[39]  L. Zacharski.  Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathy. , 2002, Cancer letters.

[40]  R. Kole,et al.  Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. , 1991, Life sciences.

[41]  N. Seeman,et al.  Design and self-assembly of two-dimensional DNA crystals , 1998, Nature.

[42]  A. Blum,et al.  Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up , 2003, Gut.

[43]  Jens Kurreck,et al.  Antisense technologies. Improvement through novel chemical modifications. , 2003, European journal of biochemistry.

[44]  D. Patel,et al.  Structural features of a three-stranded DNA junction containing a C-C junctional bulge. , 1993, Biochemistry.